Items where authors include "Perren, T"

Export as [feed] Atom [feed] RSS
Number of items: 23.

Article

Twelves, C, Cheeseman, S, Sopwith, W et al. (9 more authors) (2020) Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre. BMC Cancer, 20 (1). 53. ISSN 1471-2407

Blagden, SP, Cook, AD, Poole, C et al. (16 more authors) (2020) Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. The Lancet Oncology, 21 (7). pp. 969-977. ISSN 1470-2045

Schmid, P, Abraham, J, Chan, S et al. (26 more authors) (2020) Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Journal of Clinical Oncology, 38 (5). pp. 423-433. ISSN 0732-183X

Clamp, AR, James, EC, McNeish, IA et al. (26 more authors) (2019) Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. The Lancet, 394 (10214). pp. 2084-2095. ISSN 0140-6736

Hollis, RL, Churchman, M, Michie, CO et al. (13 more authors) (2019) High EMSY expression defines a BRCA‐like subgroup of high‐grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum. Cancer, 125 (16). pp. 2772-2781. ISSN 0008-543X

Gore, M, Hackshaw, A, Brady, WE et al. (19 more authors) (2019) An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor. Gynecologic Oncology, 153 (3). pp. 541-548. ISSN 0090-8258

González Martin, A, Oza, AM, Embleton, AC et al. (13 more authors) (2019) Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. Gynecologic Oncology, 152 (1). pp. 53-60. ISSN 0090-8258

Khoja, L, Nolan, K, Mekki, R et al. (14 more authors) (2016) Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK. Clinical Oncology, 28 (12). pp. 760-765. ISSN 0936-6555

Wallington, M, Saxon, EB, Bomb, M et al. (11 more authors) (2016) 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study. Lancet Oncology, 17 (9). pp. 1203-1216. ISSN 1470-2045

Storr, SJ, Zhang, S, Perren, T orcid.org/0000-0001-8472-8856 et al. (6 more authors) (2016) The calpain system is associated with survival of breast cancer patients with large but operable inflammatory and non-inflammatory tumours treated with neoadjuvant chemotherapy. Oncotarget, 7 (30). pp. 47927-47937. ISSN 1949-2553

Fatayer, H, Sharma, N, Manuel, D et al. (7 more authors) (2016) Serial MRI scans help in assessing early response to neoadjuvant chemotherapy and tailoring breast cancer treatment. European Journal of Surgical Oncology, 42 (7). pp. 965-972. ISSN 0748-7983

Gahlaut, R, Bennett, A, Fatayer, H et al. (7 more authors) (2016) Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist. European journal of cancer, 60. pp. 40-48. ISSN 0959-8049

Hall, M, Gourley, C, Mcneish, I et al. (6 more authors) (2013) Targeted anti-vascular therapies for ovarian cancer: Current evidence. British Journal of Cancer, 108 (2). pp. 250-258. ISSN 0007-0920

Pinhel, I, Hills, M, Drury, S et al. (27 more authors) (2012) ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Research, 14 (2). R46. ISSN 1465-5411

Harries, M, Moss, C, Perren, T orcid.org/0000-0001-8472-8856 et al. (10 more authors) (2004) A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer. British Journal of Cancer, 91 (4). pp. 627-632. ISSN 0007-0920

Judson, IR, Calvert, AH, Gore, ME et al. (4 more authors) (1991) Phase II trial of trimelamol in refractory ovarian cancer. British Journal of Cancer, 63 (2). pp. 311-313. ISSN 0007-0920

Hardy, J, Smith, I, Cherryman, G et al. (4 more authors) (1990) The value of computed tomographic (CT) scan surveillance in the detection and management of brain metastases in patients with small cell lung cancer. British Journal of Cancer, 62 (4). pp. 684-686. ISSN 0007-0920

Selby, P, Patel, P, Milan, S et al. (7 more authors) (1990) ChlVPP combination chemotherapy for Hodgkin's disease: long-term results. British Journal of Cancer, 62 (2). pp. 279-285. ISSN 0007-0920

Conference or Workshop Item

You, B, Tod, M, Leary, A et al. (12 more authors) (2020) Preponderant impact of the chemosensitivity assessed by the modeled CA-125 kinetic parameter KELIM on the success of the first line treatment: Pooled analysis of AGO-OVAR 7, AGO-OVAR 9 and ICON7 trials--a GINECO-GINEGEPS study. In: 51st Annual Meeting of the Society of Gynecologic Oncology, 28-31 Mar 2020, Toronto, Canada.

Stavraka, C, Evans, TRJ, Dunlop, J et al. (6 more authors) (2020) Abstract P2-16-15: 10-year outcome for women randomized in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: An anglo-celtic cooperative oncology group study. In: Abstracts: 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas, 10-14 Dec 2019, San Antonio, Texas, USA.

Schmid, P, Abraham, J, Chan, S et al. (17 more authors) (2018) AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. In: 2018 ASCO Annual Meeting, 01-05 Jun 2018, Chicago, IL, USA.

Proceedings Paper

Twelves, C, Cheeseman, S, Thompson, M et al. (8 more authors) (2019) "Real world" characteristics, treatment patterns and outcomes of patients with hormone receptor positive (HR plus ), human epidermal growth factor 2 negative (HER2-) metastatic breast cancer (MBC). In: Cancer Research. 2018 San Antonio Breast Cancer Symposium, 04-08 Dec 2018, San Antonio, Texas, USA. American Association for Cancer Research .

Cheeseman, S, Thompson, M, Riaz, M et al. (9 more authors) (2018) Characteristics and treatment patterns in patients with locally advanced and metastatic hormone receptor positive (HR+ ), human epidermal growth factor 2 negative (HER2-) breast cancer in clinical practice: retrospective analysis from Leeds Cancer Centre. In: Value in Health. ISPOR Europe 2018, 10-14 Nov 2018, Barcelona, Spain. Elsevier , S51-S51.

This list was generated on Sun Mar 24 12:58:57 2024 GMT.